Enhertu received EU approval as adjuvant treatment for HER2-positive early Breast cancer

NMPA accepted the new indication application for sac-TMT plus pembrolizumab as 1L treatment for PD-L1-negative...

China’s NMPA accepted the application for Disitamab vedotin plus subcutaneous Toripalimab for HER2-expressing Urothelial carcinoma

VitsGen Therapeutics receives FDA ODD for FAP-Targeted Radiopharmaceutical 177Lu-FAP-VG11

AimedBio and Boehringer Ingelheim initiate Phase 1 study of ADC BI 4060107

Xilio Therapeutics dosed the first patient in the Phase 1/2 trial of XTX501 for metastatic...